CA1054052A - Methode simplifiee pour la preparation d'un concentre de facteur viii hautement purifie - Google Patents

Methode simplifiee pour la preparation d'un concentre de facteur viii hautement purifie

Info

Publication number: CA1054052A
Authority: CA; Canada
Prior art keywords: factor viii; fibrinogen; cryoprecipitate; percent; concentrate
Prior art date: 1976-08-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA258,324A

Other languages

English (en)

Inventor

Edward Shanbrom

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

RECHERCHES HEMATOLOGIQUES SA

Original Assignee

RECHERCHES HEMATOLOGIQUES SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-08-14

Filing date

1976-08-03

Publication date

1979-05-08

1976-08-03 Application filed by RECHERCHES HEMATOLOGIQUES SA filed Critical RECHERCHES HEMATOLOGIQUES SA

1979-05-08 Application granted granted Critical

1979-05-08 Publication of CA1054052A publication Critical patent/CA1054052A/fr

Status Expired legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 37
229960000301 factor viii Drugs 0.000 title claims abstract description 34
239000012141 concentrate Substances 0.000 title claims abstract description 14
238000002360 preparation method Methods 0.000 title abstract description 5
108010054218 Factor VIII Proteins 0.000 claims abstract description 32
102000001690 Factor VIII Human genes 0.000 claims abstract description 32
229940012952 fibrinogen Drugs 0.000 claims description 23
108010049003 Fibrinogen Proteins 0.000 claims description 22
102000008946 Fibrinogen Human genes 0.000 claims description 22
239000007788 liquid Substances 0.000 claims description 16
238000001816 cooling Methods 0.000 claims description 11
239000000047 product Substances 0.000 claims description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
239000006228 supernatant Substances 0.000 claims description 7
239000007858 starting material Substances 0.000 claims description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
102000004169 proteins and genes Human genes 0.000 claims description 5
108090000623 proteins and genes Proteins 0.000 claims description 5
239000011780 sodium chloride Substances 0.000 claims description 5
239000012153 distilled water Substances 0.000 claims description 4
230000001376 precipitating effect Effects 0.000 claims description 4
238000003860 storage Methods 0.000 claims description 4
150000002632 lipids Chemical class 0.000 claims description 3
229920005862 polyol Polymers 0.000 claims description 3
150000003077 polyols Chemical class 0.000 claims description 3
238000001179 sorption measurement Methods 0.000 claims description 3
239000012736 aqueous medium Substances 0.000 claims description 2
238000004090 dissolution Methods 0.000 claims description 2
230000007774 longterm Effects 0.000 claims description 2
230000000087 stabilizing effect Effects 0.000 claims description 2
230000001954 sterilising effect Effects 0.000 claims description 2
239000000203 mixture Substances 0.000 claims 1
238000001556 precipitation Methods 0.000 abstract description 13
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 21
102100026735 Coagulation factor VIII Human genes 0.000 description 20
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
238000000605 extraction Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
229920001223 polyethylene glycol Polymers 0.000 description 5
239000004471 Glycine Substances 0.000 description 4
208000006454 hepatitis Diseases 0.000 description 4
231100000283 hepatitis Toxicity 0.000 description 4
238000000746 purification Methods 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000012467 final product Substances 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
241000700605 Viruses Species 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
229940024545 aluminum hydroxide Drugs 0.000 description 2
230000000603 anti-haemophilic effect Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000011109 contamination Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
230000001698 pyrogenic effect Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
239000002002 slurry Substances 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
241000370685 Arge Species 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
108010035369 Cohn fraction I Proteins 0.000 description 1
239000001263 FEMA 3042 Substances 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
102000018721 Macroglobulins Human genes 0.000 description 1
108010091934 Macroglobulins Proteins 0.000 description 1
LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000007792 addition Methods 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000002844 continuous effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
102000057593 human F8 Human genes 0.000 description 1
229960000900 human factor viii Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
-1 poly(oxyethylene) Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
229940033123 tannic acid Drugs 0.000 description 1
235000015523 tannic acid Nutrition 0.000 description 1
229920002258 tannic acid Polymers 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229940078499 tricalcium phosphate Drugs 0.000 description 1
229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
238000010792 warming Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

CA258,324A 1976-08-14 1976-08-03 Methode simplifiee pour la preparation d'un concentre de facteur viii hautement purifie Expired CA1054052A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19762636757 DE2636757C2 (de)	1976-08-14	1976-08-14	Verfahren zum Aufkonzentrieren und Reinigen des Antihämophiliefaktors

Publications (1)

Publication Number	Publication Date
CA1054052A true CA1054052A (fr)	1979-05-08

Family

ID=5985522

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA258,324A Expired CA1054052A (fr)	1976-08-14	1976-08-03	Methode simplifiee pour la preparation d'un concentre de facteur viii hautement purifie

Country Status (7)

Country	Link
JP (1)	JPS5910645B2 (fr)
AT (1)	AT349639B (fr)
CA (1)	CA1054052A (fr)
DE (1)	DE2636757C2 (fr)
GB (1)	GB1551928A (fr)
NL (1)	NL177181C (fr)
SE (1)	SE448274B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4302445A (en) *	1980-01-18	1981-11-24	Institut Merieux	Method for concentrating and purifying antihemophilic factor or factor VIII
AT369263B (de)	1980-08-27	1982-12-27	Immuno Ag	Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates
JPS5867627A (ja) *	1981-10-12	1983-04-22	ア−マ−・フア−マシユ−テイカル・カンパニ−	高純度抗血友病性因子の製造法
DE3318521A1 (de) *	1983-05-20	1984-11-22	Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München	Verfahren zur herstellung eines antihaemophiliefaktor-konzentrats
AT379510B (de) *	1983-05-20	1986-01-27	Immuno Ag	Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation
CA1293941C (fr) *	1985-11-08	1992-01-07	Maria Erlinda Co-Sarno	Methode pour preparer un facteur antihenophile (fah) par precipitation a froid et pour ameliorer la solubilite du fah recupere
EP0238701B1 (fr) *	1986-03-27	1992-03-18	Octapharma AG	Procédé de production d'un facteur anti-hémophilique hautement purifié
AT391808B (de) *	1986-11-03	1990-12-10	Immuno Ag	Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
DE3926034C3 (de) *	1989-08-07	1996-11-21	Behringwerke Ag	Verfahren zur Herstellung eines stabilen Faktors VIII
AU770634B2 (en) *	1998-06-23	2004-02-26	Shanbrom Technologies, Llc	Method and apparatus for the production of purified plasma proteins
WO2000061776A1 (fr) *	1999-04-14	2000-10-19	Mercian Corporation	Derives de vitamine d et procede de production correspondant
DE102004009400A1 (de)	2004-02-24	2005-09-08	Zlb Behring Gmbh	Fibrinogen Reinigung
JP7110360B2 (ja)	2017-10-09	2022-08-01	テルモビーシーティーバイオテクノロジーズ，エルエルシー	凍結乾燥方法
CN113597532B (zh)	2019-03-14	2023-02-17	泰尔茂比司特生物技术有限公司	冻干容器填充固定装置、系统及使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2543808A (en) *	1946-12-26	1951-03-06	Parke Davis & Co	Method of preparing fibrinogen
GB1507198A (en) *	1974-04-12	1978-04-12	Squibb & Sons Inc	Antihemophilic factor

1976
- 1976-08-03 CA CA258,324A patent/CA1054052A/fr not_active Expired
- 1976-08-05 GB GB3258876A patent/GB1551928A/en not_active Expired
- 1976-08-12 SE SE7609012A patent/SE448274B/xx unknown
- 1976-08-14 DE DE19762636757 patent/DE2636757C2/de not_active Expired
- 1976-08-17 AT AT611376A patent/AT349639B/de not_active IP Right Cessation
- 1976-08-23 JP JP51099638A patent/JPS5910645B2/ja not_active Expired
- 1976-08-23 NL NL7609349A patent/NL177181C/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
JPS5326313A (en)	1978-03-11
SE448274B (sv)	1987-02-09
GB1551928A (en)	1979-09-05
ATA611376A (de)	1978-09-15
NL177181C (nl)	1985-08-16
JPS5910645B2 (ja)	1984-03-10
SE7609012L (sv)	1978-02-13
AT349639B (de)	1979-04-10
DE2636757A1 (de)	1978-02-16
NL177181B (nl)	1985-03-18
DE2636757C2 (de)	1984-07-05
NL7609349A (nl)	1978-02-27

Publication	Publication Date	Title
US4188318A (en)	1980-02-12	Simplified method for preparation of high yield, high purity Factor VIII concentrate
US4069216A (en)	1978-01-17	Simplified methods for preparation of very high purity Factor VIII concentrate
US4203891A (en)	1980-05-20	Method of collecting anti-hemophilic factor VIII from blood and blood plasma using heparin or sodium heparin
US4105650A (en)	1978-08-08	Method of preserving blood plasma i
CA1054052A (fr)	1979-05-08	Methode simplifiee pour la preparation d'un concentre de facteur viii hautement purifie
JP3094167B2 (ja)	2000-10-03	免疫血清グロブリンの精製方法
EP0047216B1 (fr)	1985-04-03	Procédé pour accroître sélectivement le rendement et la pureté de protéines cryoprécipitées
CA1243950A (fr)	1988-11-01	Procede de production d'un concentre de facteur antihemophilique hautement purifie
US4027013A (en)	1977-05-31	Clottable fibrinogen free factor VIII and albumin product and process
JPH04243899A (ja)	1992-08-31	第ｖｉｉｉ因子の精製およびこの方法で得られた第ｖｉｉｉ因子
US4087415A (en)	1978-05-02	Antithrombin III
US4387092A (en)	1983-06-07	Process for the preparation of factor VIII concentrate
CA1297011C (fr)	1992-03-10	Methode de production d'une fraction contenant le facteur viii (ahf)
EP0221566B1 (fr)	1992-08-12	Procédé de préparation du facteur antihémophilique (AHF) par précipitation par le froid et d'amélioration de la solubilité de l'AHF receuilli
US4057628A (en)	1977-11-08	Removal of hepatitis associated antigen from plasma
EP1928915B1 (fr)	2012-01-18	Preparation d'immunoglobuline intraveineuse a tres haut rendement
US4137223A (en)	1979-01-30	Method of preserving blood plasma II
JPS6242887B2 (fr)	1987-09-10
US4406886A (en)	1983-09-27	Purification of antihemophilia factor VIII by precipitation with zinc ions
US4189425A (en)	1980-02-19	Method of preserving blood plasma I
US3038838A (en)	1962-06-12	Method of producing purified properdin
DK146098B (da)	1983-06-27	Fremgangsmaade til rensning af faktor viii (antihemofil faktor)
Wickerhauser	1980	METHODS FOR PREPARATION OF CLINICAL FACTOR VIII CONCENTRATES
NO149610B (no)	1984-02-13	Fremgangsmaate for rensing av den antihemofile faktor, faktor viii
KR20040015053A (ko)	2004-02-18	혈장, 동결침전물 또는/및 혈소판을 포함하는 혈액생성물의 살균 또는 제조 향상용 시트르산을 포함하는카복실산